Scarica l'app Stockscreener
30.61
4.73%
-1.52
Dopo l'orario di chiusura:
31.05
0.44
+1.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$32.13
Aprire:
$32.35
Volume 24 ore:
3.47M
Relative Volume:
1.63
Capitalizzazione di mercato:
$4.06B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-5.8194
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
-9.89%
1M Prestazione:
-20.80%
6M Prestazione:
-45.30%
1 anno Prestazione:
-47.12%
Intervallo 1D:
$30.46
$32.95
Intervallo di 1 settimana:
$30.46
$35.36
Portata 52W:
$30.46
$61.40
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
30.61 | 4.06B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics Unusual Options Activity - Nasdaq
Cytokinetics gets an ‘incremental’ win for delayed heart drug - Endpoints News
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Cytokinetics stock rises on Phase 3 trial win (CYTK:NASDAQ) - Seeking Alpha
Cytokinetics (CYTK) Reports Positive Results from Phase 3 Clinical Trial | CYTK Stock News - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | CYTK Stock News - GuruFocus
Aficamten outperforms beta blocker in HCM trial - Investing.com
Cytokinetics' heart disease drug meets main goal in late-stage study - marketscreener.com
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - Eagle-Tribune
Dimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
5,400 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Raymond James Financial Inc. - Defense World
Cytokinetics, Incorporated Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- CYTK - ACCESS Newswire
FY2025 EPS Estimates for Cytokinetics Lowered by Analyst - Defense World
Barclays Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $53.00 - Defense World
HC Wainwright Has Weak Estimate for Cytokinetics Q2 Earnings - Defense World
What is B. Riley’s Estimate for Cytokinetics Q2 Earnings? - Defense World
Leerink Partnrs Predicts Lower Earnings for Cytokinetics - Defense World
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Royal Bank of Canada Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress - Stock Titan
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Cytokinetics (CYTK) Maintains Overweight Rating Despite Price Target Cut | CYTK Stock News - GuruFocus
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating - marketscreener.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cytokinetics shares hold as JMP reiterates $78 price target By Investing.com - Investing.com Nigeria
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month Low Following Analyst Downgrade - Defense World
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights By Investing.com - Investing.com Nigeria
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
CYTK: Citigroup Lowers Price Target for Cytokinetics | CYTK Stoc - GuruFocus
Cytokinetics Inc earnings beat by $0.01, revenue fell short of estimates - Investing.com Nigeria
Cytokinetics to Hold Annual Meeting of Stockholders - Stock Titan
Cytokinetics (CYTK) Price Target Adjusted by RBC Capital | CYTK Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended - Yahoo Finance
Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook - Seeking Alpha
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com Australia
Cytokinetics (CYTK) Price Target Adjusted as FDA Decision Delayed | CYTK Stock News - GuruFocus
Cytokinetics shares hold as JMP reiterates $78 price target - Investing.com
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges By GuruFocus - Investing.com Canada
Cytokinetics (CYTK) Advances Aficamten Commercialization Plans - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics: Q1 Earnings Snapshot - The Washington Post
Cytokinetics (CYTK) Misses Q1 Revenue Estimates and Advances Car - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings: EPS of -$1.36 Beats Es - GuruFocus
Earnings call transcript: Cytokinetics reports Q1 2025 net loss, stock dips - Investing.com India
Cytokinetics Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):